Articles tagged with Cancer
Scientists at Salk Institute discovered that removing bile acid-creating protein BAAT and adding bile acid UDCA controls tumor growth in mice with liver cancer. UDCA supplements may be a quick solution to improving liver cancer patient outcomes.
Researchers from the Keck School of Medicine of USC found an association between levels of manmade “forever chemicals” in drinking water and certain digestive, endocrine, respiratory, and mouth and throat cancers. The study estimated that PFAS contamination contributes to 6,864 cancer cases per year.
A three-drug cocktail of drugs has been identified as a potential booster of CAR-T cancer therapy by researchers at the University of North Carolina. The cocktail preserves a critical cell subset called T-memory stem cells, which are crucial for long-term persistence of CAR-T cells.
The study found that COVID-19-related disruptions led to frequent delays in investigations or treatments for children with brain tumors. Caregivers reported feeling traumatized by their experiences, including lack of access to healthcare facilities and social situations, which made it harder to evaluate their concerns.
Researchers at University of California San Diego School of Medicine have discovered that fatty liver disease can lead to liver cancer through DNA damage in liver cells. The study suggests that developing new drugs to prevent or reverse DNA damage could be a promising approach for preventing liver cancer.
Researchers found 84 rare, large chromosomal abnormalities associated with pediatric solid tumors, primarily inherited from unaffected parents. Smaller gene-disruptive germline SVs also identified as risk factors for childhood cancers.
The ChiTaRS 8.0 database is the world's largest collection of chimeric genes found in humans with cancer and other chronic diseases. It enables the precise adaptation of treatments to specific cancer types, improving treatment success and minimizing side effects.
Cancer-associated fibroblasts (CAFs) interact with immune cells, extracellular matrix, and tumor cells, leading to immunosuppression and tumor proliferation. CAFs also regulate metabolism and ECM formation, contributing to tumor progression.
The European Society of Endocrinology (ESE) and ESE Foundation will host the first-ever World Hormone Day on April 24, 2025. The campaign aims to raise public awareness of good hormone health and improve national political engagement for better prevention, diagnosis, and treatment of endocrine disease.
Recent advancements in metastatic brain tumors offer hope for treatment. The integration of multi-omics technologies and cutting-edge therapies is shedding new light on the intricate landscape of brain metastasis.
Dr. Gerta Hoxhaj has been recognized with the 2025 Mary Beth Maddox Award and Lectureship for her groundbreaking work on cancer metabolism. Her research focuses on understanding the connections between signaling networks and metabolic pathways in cancer cells, revealing new mechanisms crucial for tumor growth.
Scientists at Goethe University Frankfurt have discovered a new way to tailor natural killer cells to target leukemia cells, improving their efficacy. The researchers used CRISPR/Cas9 gene editing to disable an immune checkpoint, allowing the modified cells to attack cancer cells more effectively.
Scientists at the University of Plymouth are creating a humanised meningioma model to study interactions between immune cells and tumour cells, enabling the development of effective therapies for NF2-related schwannomatosis. The model will be made available worldwide to test new treatments and reduce clinical trial delays.
EBViously aims to prevent infectious mononucleosis and secondary diseases such as ME/CFS, while also protecting against certain types of cancer. The company's innovative vaccine candidate uses virus-like particles derived from EBV to trigger a targeted immune response.
Researchers identified YTHDF2 as a key player in advancing blood cancers, which can help cancer cells evade immune system detection. A new compound CCI-38 targets and suppresses YTHDF2, reducing aggressive blood cancer growth.
A new study detects pre-malignant pancreatic lesions using Diffusion Tensor Imaging (DTI), a form of MRI, which could enable early diagnosis and effective therapies. The detection was successful in both transgenic mice and human samples, opening the way to non-invasive diagnostic tools for PanINs.
A new screening method combining laser analysis with AI identifies patients with breast cancer in its earliest stage, stage 1a. This non-invasive technique reveals subtle changes in the bloodstream that occur during the initial phases of the disease, outperforming existing early detection strategies.
Researchers at Salk Institute establish a novel framework for the relationship between nutrition and cell identity. They found that a nutritional switch from acetate to citrate plays a key role in determining T cell fates, shifting them from active effector cells to exhausted cells.
Glioblastoma brain tumors synchronize their growth with the daily release of steroid hormones like cortisol, according to new research. Blocking these signals slows tumor growth and disease progression in animal models.
Women with low-risk ductal carcinoma in situ reported similar experiences undergoing active monitoring versus guideline-concordant care. The study found that both approaches had comparable lived experiences during the 2-year follow-up period.
Researchers discovered a protein variant acting like a tuning dial to regulate interferon signaling, impacting immune function and disease susceptibility. The balance between this variant and the normal protein may vary from person to person, contributing to individual differences in immune responses.
A new study finds that not attaining a high school degree is associated with higher cancer mortality, while high allostatic load, a marker of chronic stress, also increases the risk. The researchers emphasize the need for educational attainment promotion and addressing social determinants of health to reduce cancer disparities.
A phase 3 trial shows that autologous stem cell transplants do not improve survival for mantle cell lymphoma patients in complete remission and undetectable minimal residual disease. Patients who remain MRD-positive after induction may benefit from ASCT, but longer follow-up is needed to confirm these findings.
A new diagnostic test uses a unique molecular 'finger print' to detect different types of cancer, with near-perfect accuracy, and could lead to earlier detection and improved patient outcomes. The test targets ribosomal RNA molecules, which are modified differently in healthy and diseased tissues.
Researchers at the University of Ottawa have developed a nanoparticle strategy to deliver both mRNA and siRNA, enhancing and interfering with multiple gene and protein expressions. This approach holds significant promise for treating major diseases like cancer and cardiovascular diseases.
The study presents strong overall responses with a triplet regimen including a novel menin inhibitor, achieving an 82% overall response rate in relapsed or refractory acute myeloid leukemia patients. The combination also demonstrated manageable side effects and significant clinical benefits, providing patients with improved treatment o...
A global clinical trial has shown a significant improvement in disease-free survival rates for children with B-cell acute lymphoblastic leukemia (B-ALL) by combining standard chemotherapy with blinatumomab, an immunotherapy. The study found improved survival rates of up to 97.5% after three years, compared to 90% with chemotherapy alone.
A recent NIH study found that prevention and screening interventions saved an estimated 4.75 million lives between 1975 and 2020, surpassing the impact of treatment advances for five major cancer types: breast, cervical, colorectal, lung, and prostate cancers.
A team of UNC-Chapel Hill researchers will develop an oncology health learning system using AI-ready data to generate real-time identification of new cancer cases and support personalized treatments. The project aims to improve cancer diagnosis, care equity, and quality by creating accessible tools for health providers.
A new study improves breast cancer risk prediction by analyzing up to three years of previous mammograms, identifying individuals at high risk 2.3 times more accurately than the standard method. The AI method considers subtle changes in mammogram images and holds up well across diverse settings.
The study estimated that prevention, screening, and treatment efforts in the US led to an average of 8 out of 10 cancer deaths being avoided for breast, cervical, colorectal, lung, and prostate cancers combined. The total number of averted cancer deaths was approximately 5.94 million between 1975 and 2020.
Engineers at USC Viterbi School of Engineering have developed a new CRISPR toolkit that allows for precise, remote-controlled genome editing using focused ultrasound. This breakthrough enables the treatment of various genetic disorders and diseases by activating or silencing specific genes with precision.
The American College of Surgeons' annual cancer report reveals that breast, bladder, and pancreatic cancers are increasingly treated with personalized therapies before surgery. Cancer stage at diagnosis remains a significant factor in determining patient survival rates.
A series of five papers highlights critical public health challenges related to cancer control in eight SAARC countries and the Rohingya refugee population in Bangladesh. The studies identify barriers contributing to significant disparities in cancer outcomes and actionable solutions to address these challenges.
A new study suggests that addressing plastic pollution could play a critical role in lowering breast cancer rates. Researchers identified nearly half of the chemicals linked to breast cancer risk as being used in plastics, including 175 potential carcinogens that should be prioritized for regulatory action.
The ESMO Asia Congress 2024 will focus on multidisciplinary oncology in the Asian region, featuring novel treatment modalities, management of specific cancer types and pan-Asian trials. Key highlights include insights into genetics, biology and practice differences between West and Asia.
Researchers discovered that cancer grows uniformly throughout its mass, with every region equally active and potentially harboring aggressive mutations. This finding challenges the traditional 'two-speed' entity model of tumors, where rapidly dividing cells on the surface and slower activity in the core were thought to exist.
A comprehensive epigenetic database of over 200 malignant cell lines has been developed, offering valuable insights into leukemia and lymphoma. The database allows researchers to predict drug sensitivity based on epigenetic lesions, aiding in tumour diagnosis and treatment.
A randomized phase 3 trial found that adding temozolomide to radiation therapy improves long-term survival for adult patients with low-grade gliomas. The 10-year survival rate was 70% with combined treatment, compared to 47% with radiation alone.
Children's Hospital of Philadelphia researchers discovered a gene signature that identifies patients with T-ALL at high risk of relapse. The study found a potential therapeutic treatment, venetoclax, which targets specific cells associated with poor outcomes.
Researchers studied ovarian cancer cell migration patterns on soft and stiff surfaces, finding that epithelioid cells are more migratory than mesenchymal cells on stiffer matrices. The study used a novel software toolkit to analyze cell behavior over time, revealing a unique 'slip' movement pattern in epithelioid cells.
A cohort study reveals racial and ethnic variations in early-onset colorectal cancer mortality, with Native Hawaiian or Other Pacific Islander and non-Hispanic Black individuals facing the highest burden. Social determinants of health play a significant role in explaining these disparities.
A clinical trial found that cetuximab was more effective than durvalumab in treating advanced squamous cell carcinoma of the head or neck, with a higher probability of being alive and free of disease at two years. Cetuximab's efficacy was similar whether or not the cancer was associated with HPV.
Sylvester researchers will present over 130 studies at ASH 2024, addressing disparities in gastric cancer. Frank J. Penedo's research highlights worse outcomes for patients with unmet supportive needs, while Shria Kumar's work seeks answers for disparities in gastric cancer among specific minorities.
Researchers at the University of Mississippi have developed a new cancer treatment method that uses glycopolymers to coat nanoparticles, reducing immune response and increasing drug delivery. This breakthrough could lead to more effective cancer treatments with reduced side effects.
Researchers at the University of Tokyo have developed a new CRISPR-based system to label small extracellular vesicles (sEVs) with RNA barcodes, enabling comprehensive analysis of their biogenesis and release regulators. This system allows for the simultaneous study of thousands of genes and estimation of sEV release from host cells.
Researchers developed a novel Ramanome-based Metastasis Index to rapidly and accurately assess cancer cells' metastatic potential. The tool combines single-cell Raman spectra with machine learning, providing a comprehensive molecular profile of cancer cells and highlighting lipid-related peaks as key determinants.
The EMA's orphan designation for G2B-002 marks a significant milestone in the fight against pediatric brain tumors. The innovative product leverages Gate2Brain's proprietary technology to enhance drug delivery across the blood-brain barrier, promising enhanced effectiveness and safety for complex cancer treatments.
The conference explores molecular determinants of cancer therapy resistance, a major challenge in the fight against cancer. Researchers discuss new therapeutic approaches and address resistance mechanisms involving tumour cells and the tumour microenvironment.
Researchers at Anglia Ruskin University are investigating the complex relationship between fat tissue and colorectal cancer. The study aims to enhance knowledge of the tumour microenvironment, uncover new molecules crucial for cancer growth, and develop more effective treatments.
Researchers at Auburn University have discovered a new way to make a cancer-targeting protein complex more stable, opening doors to better cancer treatments. By adjusting the attachment points on PD-L1, they found that the complex can become up to four times stronger and grow more stable under tension.
Testicular cancer is a highly treatable condition with high survival rates when detected early, but patients with the highest-risk disease face a lower prognosis. New genetic changes have been identified using whole genome sequencing, offering potential new treatment strategies.
A new award at University of Utah Health recognizes the importance of a diverse scientific community. The Administrative Supplement to Recognize Excellence in Diversity, Equity, Inclusion, and Accessibility (DEIA) Mentorship award aims to enhance diversity, equity, inclusion, and accessibility in biomedical sciences.
Researchers have discovered that metabolic enzymes play a crucial role in maintaining the integrity of the human genome by orchestrating critical functions like cell division and DNA repair. This discovery could lead to new cancer therapies, particularly for triple-negative breast cancer, by exploiting its metabolic vulnerabilities.
A new study introduces the Meuhedet Electronic Frailty Index (MEFI) to assess frailty in older people and identify those at risk for serious health outcomes. The index classifies individuals as 'fit,' 'mildly frail,' or 'severely frail' and has been shown to predict mortality and hospitalization with high accuracy.
Researchers at the University of Pittsburgh found that blocking the uptake of lactic acid, a key factor in T cell exhaustion, can reinvigorate these cells. This new approach shows promise for improving tumor control and treatment outcomes in various cancers.
A new study uses CRISPR-Cas13 to identify nearly 800 noncoding RNAs that are functional and essential for cell function, including in cancer and human development. The researchers found that these RNA molecules modulate key pathways for cell proliferation and can serve as potential biomarkers and therapeutic targets for cancer treatment.
Scientists at WashU Medicine have successfully forced glioblastoma cells to display immune system targets, potentially making them vulnerable to immunotherapies. The strategy involves a combination of two FDA-approved epigenetic therapy drugs that induce the production of unusual proteins called neoantigens.
Researchers at Michigan Medicine found that SLC13A3 transporter impairs tumor immunity by endowing ferroptosis resistance. This discovery suggests a potential target for improving immunotherapy responses in cancer patients.
A new mechanism has been found by which tumor cells escape the immune system, involving a protein called IRGQ. Studies have shown that suppressing IRGQ can trigger a stronger immune response against cancer cells, leading to improved survival rates in liver cancer patients.